Can-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.com

Posted by ABMN Staff on Mar 24th, 2025

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note issued to investors on Sunday. The firm issued a sell rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, March 18th.

View Our Latest Stock Report on CANF

Can-Fite BioPharma Trading Up 6.0 %

CANF opened at $1.60 on Friday. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $1.86. The company has a market cap of $5.66 million, a price-to-earnings ratio of -0.89 and a beta of 1.12. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 58.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.